Subscribe to AfterDawn's weekly newsletter.
Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
AMSTERDAM, August 28 /PRNewswire/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today announced that it will release its financial results for the first six months of 2007 on Wednesday, August 29, 2007 at 8 am Central European Time (CET). To discuss these results, the Company will conduct a conference call at 10 am CET. Netherlands Dial In: +31-(0)800-949-4517 (toll free); US Dial In: +1-866-291-4166 (toll free); UK Dial In: +44-207-107-0611. To listen to the conference call live via the internet, visit the investor relations portion of the AMT website at www.amtbv.com. Please go to the website 15 minutes prior to the call to register, download and install the necessary audio software. About Amsterdam Molecular Therapeutics AMT has a unique gene therapy platform that to date appears to circumvent many if not all of the obstacles that have prevented gene therapy to become a mainstay of clinical medicine. Using adeno-associated viral (AAV) vectors as the delivery vehicle of choice for therapeutic genes, the company has been able to design and validate what is probably the first stable and scalable AAV production platform. As such, AMT's proprietary platform holds tremendous promise for thousands of rare (orphan) diseases that are caused by one faulty gene. AMT currently has a product pipeline with six products at different stages of development.
